Discovery of bispecific antibodies with two innovative targets may improve antibody therapy of cancer and autoimmune diseases.
Biocytogen’s High-throughput mAb platform allows bispecific antibody production. We can supply unique mAb sequences for bispecific antibody production.
Any IgG mAb sequence can be customized to be a bispecific mAb, including different valencies (2,3 or 4 binding sites), for both asymmetric and symmetric formats.
Our in vitro and in vivo experiments have been designed to support the MOA of bispecific antibodies.